Mariner
LAB icon

Mariner’s Standard BioTools LAB Stock Holding History

Mariner’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$75.3K Buy
91,537
+44,380
+94% +$41.9K ﹤0.01% 3369
2026
Q1 		$43.4K Buy
47,157
+27,529
+140% +$33.3K ﹤0.01% 3440
2025
Q4 		$25.1K Sell
19,628
-42
-0.2% -$56 ﹤0.01% 3466
2025
Q3 		$25.6K Sell
19,670
-8,521
-30% -$11.2K ﹤0.01% 3499
2025
Q2 		$33.8K Sell
28,191
-45,954
-62% -$50.9K ﹤0.01% 3378
2025
Q1 		$80.1K Buy
+74,145
New +$104K ﹤0.01% 3228
2024
Q4 		– Sell
-10,180
Closed -$19.6K – 3460
2024
Q3 		$19.6K Sell
10,180
-1,941
-16% -$3.8K ﹤0.01% 3252
2024
Q2 		$21.5K Sell
12,121
-11,507
-49% -$28.1K ﹤0.01% 3107
2024
Q1 		$64K Buy
+23,628
New +$57K ﹤0.01% 3001

Other funds holding LAB

CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
MCO
MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HBWM
Hollow Brook Wealth Management Katonah, New York $504M AUM 26.89% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Mariner's LAB Position: Q2 2026 in Review

Mariner increased its Standard BioTools (LAB) stake by 94% in Q2 2026, buying an estimated $41.9K and bringing the position to 91,537 shares worth $75.3K. The position accounts for ﹤0.01% of the portfolio, ranked #3369.

Mariner first reported a position in LAB in Q1 2024 and has held it in 9 quarters since. The position peaked at $80.1K in Q1 2025. 144 funds tracked by Wall St. Rank hold LAB as of Q2 2026.

  • Mariner held 91,537 shares of Standard BioTools worth $75.3K as of Q2 2026.
  • Mariner bought 44,380 Standard BioTools shares in Q2 2026, an estimated $41.9K.
  • Standard BioTools made up ﹤0.01% of Mariner's portfolio in Q2 2026, its #3369 holding.
  • Mariner first reported a position in Standard BioTools in Q1 2024 and has held it in 9 quarters since.
  • Mariner's Standard BioTools position peaked at $80.1K in Q1 2025.
  • 144 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2026.

Based on Mariner's 13F filing for Q2 2026, filed 13 Aug 2026.